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ABSTRACT. (+)-JD1, a rationally designed 
ferrocene analogue of the BET bromodomain 
(BRD) probe molecule (+)-JQ1, has been 
synthesized and evaluated in biophysical, cell 
based assays as well as in pharmacokinetic 
studies. It displays nM activity against BRD 
isoforms and its cocrystal structure was 
determined in complex with the first 
bromodomain of BRD4 and compared with 
that of (+)-JQ1, a known BRD4 small 
molecule probe. At 1 µM concentration, (+)-
JD1 was able to inhibit c-Myc, a key driver in 



















The study of post translational modifications (PTMs) remains a field of intense activity in 
epigenetics. Bromodomains (BRDs) are acetylated lysine (KAc) evolutionary conserved reader 
modules and are indispensable in the “write-erase-read” epigenetic code driving gene 
transcription and silencing.1 BRDs directly impact upon, inter alia, a number of cancers and 
inflammation processes.2,3,4,5 The BET bromodomain family (bromodomain and extra-terminal) 
comprises four proteins, namely bromodomain-containing proteins 2 - 4 (BRD2, BRD3, BRD4) 
and bromodomain testis-specific protein (BRDT) with each member containing two tandem N-
terminal bromodomains and an extra-terminal protein interaction domain (ET). Important 
anchoring sites for the KAc motif are provided by conserved asparagine and tyrosine residues, 
the latter via a hydrogen bond to one of four structural water molecules.6,7 
Out of the 61 BRDs in humans, BRD4 is undoubtedly the most studied, with notable progress in 
the development of probe molecules and clinical candidates, which include TEN-010, OTX015, I-
BET762 and the thienodiazepine (+)-JQ1 (Figure 1).8,9 The latter was shown to be a potent 
inhibitor of BRD4(1), and its co-crystal structure in BRD4(1) showed it to occupy the KAc binding 


































Ir(III) complex  




The incorporation of transition metal complexes into bioactive molecules can improve 
ligand exchange processes and pharmacokinetics,11,12 and enable redox behavior due to 
several accessible oxidation states.13 Moreover, it can lead to enhanced steric and 
hydrophobic interactions with the target protein, especially with bound ligands such as 
cyclopentadienyl,14 and to increased coordination numbers such as octahedral geometry 
(termed “hypervalent carbon”), beyond tetrahedral carbon. 15,16,17,18,19 
Recent studies, based on screening a library of around 30 octahedral metal complexes, 
revealed an iridium complex (Ir(III), Figure 1)20 with comparable in vitro BRD4 binding to 
(+)-JQ1 and antiproliferative in vivo activity when dosed at 100 mg/kg. In the current case, 
we present a rationally-designed metal-containing BRD4 inhibitor where we reasoned that 
the BET BRD inhibitor (+)-JQ1, described above, might be receptive to incorporation of an 
aminoferrocene bioisostere to replace the t-Bu ester group (PDB; 3MXF).21,22,23,24,25,26,27  
We describe herein the synthesis of organometallic complexes related to (+)-JQ1, and 
their biological and pharmacokinetic evaluation. 
RESULTS AND DISCUSSION 
After deprotection of commercially available (+)-JQ1, standard coupling chemistry led to 
the ferrocene-substituted amide analogues (+)-JD1 and (+)-JD2, which were 
characterized by 1H and 13C NMR spectroscopy and were >95% pure by HPLC and by 
chiral HPLC (Scheme 1). This was verified by the synthesis of (-)- or racemic JD1 and JD2 
as HPLC and assay controls (Figure S5-10).  
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A co-crystal structure determination of (+)-JD1 in complex with the first BRD of BRD4 was 
performed (Figure 2 (a)). From the (+)-JQ1 structure (Figure 2 (c); see PDB; 3MXF), the t-butyl 
ester substituent nestles into the small depression created by the side-chains of Leu92 and 
Leu94. The interaction is quite tight and as a result, there is no space for a water molecule to 
interact with the alkoxy group although the ester carbonyl group forms H-bonds with well-defined 
water molecules around it. The electron density map for the ferrocene group of (+)-JD1 was 
initially ambiguous. An anomalous difference Fourier map from data collected just below the Fe 
K-edge showed two peaks with an r.m.s. density of 8.9 and 7.5, respectively. Hence, the ferrocene 
moiety was modelled in two conformations with occupancies of 0.66 (yellow) and 0.34 (magenta), 
respectively (Figure S11). The B-factors for the ((+)-JQ1-like) core of (+)-JD1 are similar to the 
surrounding protein residues. However, they, unsurprisingly, go up towards the ferrocene group. 
Both (+)-JQ1 and (+)-JD1 form hydrogen bonds with surrounding water molecules although the 
carbonyl group of (+)-JD1 points into the opposite direction to the one in (+)-JQ1 (Figure 2(c)). 
We anticipated that (+)-JD1 would be less potent, due to the different conformations adopted, 
than (+)-JQ1. 
With the new complexes to hand, we next looked to evaluate them biologically. (+)-JD1 and (+)-
JD2 were titrated, alongside (+)-JQ1,  against all somatic human BET bromodomains (BRD 2-4,  
BD1, BD2) in an AlphaLISA assay, which measures the displacement of a biotinylated JQ1 
analogue, Bio-JQ128,29 using a modification of a known procedure.30 In general, mean pIC50 
values (negative log of the IC50 value, converted to molar; the corresponding respective IC50 
values are given in parentheses) were obtained with (+)-JQ1 = 7.0 (150 nM) compared with (+)-
JD1 = 6.5 (400 nM), signifying a drop in potency of 0.5 log units (~3x loss). (+)-JD2 was only able 
to reach ~75% inhibition within our titrations and was visibly less potent against the BET BDs than 
(+)-JD1. IC50 curves were fitted to the (+)-JD2 data assuming an IMAX of 100%, giving a mean 
pIC50 of 6.2 (750 nM) and a pIC50 of 0.8 (~6.5x loss), although these values cannot be considered 




(a) (b)  
(c)  
Figure 2. (a) Cocrystal structure of (+)-JD1 in BRD4(1) showing two conformations of the 
ferrocene unit. (b) Superimposition of (+)-JD1 and (+)-JQ1. (c) Close-up of (+)-JQ1 (LHS) and 
(+)-JD1 (RHS) showing change of orientation of carbonyl group on moving from an ester to an 
amide. 
As a negative control, like (-)-JQ1, the (-)- enantiomer of JD1 was shown to have little biological 
activity. When tested against BRD4 BD1 in the AlphaLISA assay, no significant inhibition was 
seen below 10 µM (Fig 3 (c)).31,32  
Since (+)-JD1 was found to be more potent than (+)-JD2, it was tested head to head with (+)-JQ1, 
in cell viability assays in several cancer cell lines. (+)-JQ1 exhibited nanomolar activity against all 
cell lines tested, whereas (+)-JD1 displayed micromolar potency against a triple negative breast 
cancer (TNBC) cell line (BT-549) and a prostate cancer cell line (LNCaP), with IC50 values of 9.9 
µM and 5.2 µM, respectively (Figure 3(d)). Both (+)-JD1 and (+)-JQ1 showed the highest cell 
killing activity against the acute myeloid leukaemia (AML) cell line (MV-4-11), with IC50 values of 
230 nM and 90 nM, respectively. This drop in cellular potency is slightly higher than the drop in 









Figure 3. (a) Titration of (+)-JQ1, (+)-JD1 and (+)-JD2 against BRD4(1) and (2) in AlphaLISA 
assay. Data shown as mean ± S.E. of 2 replicate wells (b) IC50 and pIC50 (±SE) values for titrations 
against all somatic BET BDs. (b) IC50 and pIC50 (±SE) values for titrations against all somatic BET 
BDs. (c) AlphaLISA BRD4(1) assay for (-)-JQ1, (-)-JD1. (d) Cell viability with (+)-JQ1 or (+)-JD1 
treatment. Average IC50 of n=3. Data shown as mean ± S.D of triplicate wells.   
 
Previous work in our laboratory investigated the redox pharmacology of a novel ferrocene-
containing HDAC inhibitor, Pojamide,33 on colorectal cancer cells (HCT116). This study utilised 









BT-549 9.90 0.70 
LNCaP 5.20 0.19 
MV-4-11 0.23 0.09 
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and concluded that this led to enhanced DNA damage and cellular cytotoxicity in this cell line. 
Therefore, the redox properties and cytotoxicity of (+)-JD1 and its purported ferrocenium 
analogue (+)-JD1+, under similar conditions, were investigated in the cell line, MV-4-11, (Figure 
3(c)), using a CellTiter-Blue assay (Promega). The addition of SNP at 25 μM concentration, alone, 
had no effect on cell viability, as shown previously by our group by titration studies, MV-4-11 cells 
were then incubated for 72 h in the absence or presence of 100 nM (+)-JD1 or (+)-JQ1, and in 
the presence or absence of SNP and glutathione (GSH), which, was added in excess, as 
previously optimized, to eliminate SNP-induced toxicity (Figure 4(b)). As expected, (+)-JQ1 
decreased cell viability to a greater extent than (+)-JD1 when tested as a single agent. The 
addition of SNP/GSH in conjunction with (+)-JQ1 had no significant effect on cell viability in 
comparison to (+)-JQ1 alone. However, when SNP/GSH were added to (+)-JD1, there was a 
slight decrease in cell viability (by ~10%) relative to (+)-JD1 alone. Although the reduction in cell 
viability was subtle, these data support the proposed model for the dual activity of (+)-JD1, 
dependent on the oxidation state of the iron atom in the ferrocene moiety. Attempts to 
independently synthesize and isolate (+)-JD1+ were unsuccessful suggesting its generation in 







































Figure 4. Cell viability of (+)-JD1 and (+)-JQ1 +/- 25 µM sodium nitroprusside (SNP) on MV-4-11 
cells. (a). Data are presented as the means ± SD, n=3 (ns: non-significant and ****p ≤ 0.0001 
relative to DMSO). (b). Cells were treated for 72 hours with either 100 nM (+)-JD1 or 100 nM (+)-
JQ1 +/- 25 µM SNP/ 1 mM glutathione (GSH). (c) Structure of postulated (+)-JD1+. 
 
The inhibition of BET bromodomains is a known indirect strategy to inhibit c-Myc, a key driver of 
cancer, which enables cancer cell survival and division34. We, therefore, compared the expression 
of c-Myc in the presence of (+)-JQ1 and (+)-JD1 with ((+/-)) rac-JD1 as a negative control. (+)-
JD1 was able to inhibit c-Myc expression down to 1 µM concentration, comparable to that of (+)-
JQ1, whereas incomplete inhibition was seem with (racemic) (+/-)-JD1 at this concentration, 
undoubtedly due to the presence of the inactive (-)-JD1 (Figure 5(a)). qRT-PCR (quantitative real 
time PCR) was performed on total RNA from cultures treated for 16 h with (+)-JQ1 or (+)-
JD1 using  c-Myc GAPDH as a housekeeping gene. Relative gene expression was normalised 
to GAPDH, and determined by the 2^-ΔΔCt method as previously described by our group.35 This 
showed that (+)-JQ1, at 500 nM concentration, was vastly superior to (+)-JD1, even at 10 µM 
concentration. 
 
(a)   
(b)   
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Figure 5. (a) Western blot of (+)-JQ1 and (+)-JD1 with rac-JD1 vs. c-Myc.(b) Total mRNA by 
qRT-PCR in the presence of (+)-JQ1 and (+)-JD1. 
 
Finally, we evaluated the pharmacokinetic (PK) properties of (+)-JD1 vs. (+)-JQ1 in selected 
standard assays (Table 1).36  Mouse microsomal metabolism of (+)-JD1 was extremely high with 
a clearance value ca. seven times that of (+)-JQ1. This metabolism is likely to be due to the 
formation of hydroxylated products (Figure S14). Both compounds had unfavourable plasma 
protein binding. 









nt; not tested. Nd not determined.a in mouse. 
CONCLUSIONS. 
The rationally designed bromodomain inhibitor (+)-JD1 has been synthesized in high yield. It 
displayed excellent BRD affinity in biochemical assays, albeit weaker than that of (+)-JQ1, which 
was rationalized by its X-ray co-crystal structure and suboptimal binding to BRD4(1), where two 
distinct ferrocene conformations were determined. A further slight increase in cell potency was 
observed when (+)-JD1 was converted to a purported Fe(III) species in cells after treatment with 
SNP. The high rate of metabolism of (+)-JD1 calls for a more general study of metabolism in metal 
containing compounds, which may improve their application in clinical settings.37,38 Further 















Pyrene 10<x<25 nd nd nd 
Aspirin >100 nd nd nd 
 Verapamil  nt 12.5 111 89.3 
(+)-JD1 10<x<25 2.6 533 >99.9 





Solvents were used as purchased including deuterated solvents for NMR use. NMR spectra were 
recorded on a Varian NMR 400 (1H 399.5 MHz; 13C{1H} 100.5 MHz or 500 (1H 499.9 MHz; 13C{1H} 
125.7 MHz). Chemical shifts are reported in ppm. Spectra are referenced to the corresponding 
protic solvent (1H) or signals of the solvent (13C). The progress of reactions was monitored by thin 
layer chromatography (TLC) using commercially available glass silica gel plates (60 Å, F254). 
The mobile phase was usually a solvent mixture and the visualization was undertaken using UV 
light. Chromatographic purifications were carried out on an ISCO Combi Flash RF 75 or 150 PSI 
purification unit, gel columns. LC-MS purity analyses were undertaken using a 5 μm C18 110 Å 
column. Percentage purities were performed using a 30 min method in water/acetonitrile with 
0.1% formic acid (5 min at 5%, 5−95% over 20 min, 5 min at 95%) with the UV set to 254 nm. 
High-resolution mass spectrometry were carried out at the University of Sussex, as described 
elsewhere. 
AlphaLISA.  
AlphaLISA assays were carried out in 384-well, light-grey Alphaplates (PerkinElmer), with a final 
assay volume of 25 µl. Each assay component was diluted in AlphaLISA buffer (50 mM HEPES, 
100 mM NaCl, 0.1% BSA, 0.02% CHAPS, pH7.5) to 5x its intended final concentration, and added 
at a volume of 5 µl, using a 12-channel Matrix P125 multi-channel pipette (Thermo). His-tagged 
protein, biotinylated (+)-JQ1 and test compounds were added to the well, and incubated for 1 h 
at room temperature. Then, in low-light conditions, Ni+ chelator AlphaLISA acceptor beads 
(PerkinElmer) were added and incubated for 1 h, then Streptavidin-conjugated AlphaScreen 
donor beads (PerkinElmer) were added and incubated for 1 h. Alpha signal was measured in a 
Pherastar FS, using the AlphaLISA module. Dose-response curves were generated in Prism 6 
(Graphpad). Final concentrations are as follows: 100 nM his-tagged BRD, 5 nM Bio-JQ1, 1% 
DMSO, 10 µg/ml each bead.  
Cell viability. 
Cell viability was measured using the CellTiter-Glo 2.0 assay (Promega). The BET-dependent, 
AML cell-line MV4-11 was obtained from DSMZ, and cultivated in RPMI medium (Gibco) 
supplemented with 10% FBS and 1% L-glutamate (Gibco). Cells were kept in an incubator at 
37°C, 5% CO2. MV4-11 cells were diluted in media to 2X the desired final concentration, and 
dispensed into a sterile, white, clear-bottomed 384-well cell-culture microplate (Greiner Bio-one) 
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at a volume of 25 µl. Following 24 h incubation test compounds were serially diluted in media to 
2x their desired final concentration, and added to the assay plate at a volume of 25 µl. After 48 h 
incubation the assay plate was moved to room temperature for 30 minutes, then CellTiter-Glo 2.0 
reagent was added to each well at a volume of 25 µl. Following a 20 minute incubation the 
luminescence signal was read on a Pherastar FS (BMG). Dose-response curves were generated 
in Prism 6 (Graphpad). Final assay concentrations are as follows: 3x105 cells/ml, 0.05% DMSO, 
5 µM and below test compound.  
Cell culture. 
Breast cancer cell line BT-549 was sourced from the American Type Culture Collection (ATCC, 
Manassas, VA, USA), US. The human AML cell line MV4-11 was purchased from the German 
Collection of Microorganisms Cell Cultures (DSMZ, Braunschweig, Germany). The human 
prostate cancer cell line LNCaP was kindly donated by the Genome Damage and Stability Centre 
(GDSC) at the University of Sussex. Cell lines were maintained in Minimal Essential Medium with 
Glutamax and Earl’s salts (MEM, Gibco) or RPMI medium (Gibco) and supplemented with 10% 
(v/v) foetal bovine serum (FBS, Pan Biotech) at 37°C in a humidified atmosphere with 5% CO2.  
 
Cell viability. 
To assess cell viability in vitro, all cell lines were seeded into 96-well plates at various cell densities 
per 100 μL media, then treated with 0.2% (v/v) DMSO or varying concentrations of compounds 
for 72 hr. Cell viability was measured using the CellTiter-Blue reagent (Promega, Madison, WI, 
USA) with fluorescence recorded at 560Ex/590Em using a Synergy HT Multi-Detection Reader 
(BioTek, Winooski, VT, USA). Relative cell viability at a given inhibitor concentration was 
determined by comparing the fluorescence to that of DMSO treated cells. Dose-response curves 
were generated in Prism 6 (Graphpad). 
 
Purification and crystallization. 
The first bromodomain of human BRD4 (BRD4(1)) was expressed and purified as described 
previously.8 Prior to crystallization, 3 µL of 100 mM JD1 in DMSO were mixed with 100 µL 6.4 
mg/mL BRD4(1) and incubated for 2 hours at 4 °C. BRD4(1) in complex with JD1 was crystallized 
using the vapour-diffusion technique in 150 nL sitting drops containing 75 nL BRD4(1)-JD1 and 
75 nL of a reservoir solution containing 60% MPD, 0.1M MIB pH 8.0 at 4 °C. 
13 
 
Data collection and structure solution 
Prior to data collection, crystals were flash frozen in liquid nitrogen without addition of an 
additional cryo-protectant. A single-crystal dataset was collected on beamline I03 at the Diamond 
Light Source at a wavelength of 0.9762 Å. Data were integrated with XDS39 and scaled with 
AIMLESS40 up to a resolution of 1.38 Å as part of the XIA2 auto-processing pipeline41. BRD4(1)-
JD1 crystallized in space group P212121 with unit cell dimensions a = 37.52Å, b = 43.97Å, c = 
79.02Å, α = β = γ = 90°, which is similar to previously published BRD4(1) crystal structures. Initial 
refinement and map calculation was carried out with DIMPLE 42 using a ligand-free version of 
BRD4(1) (PDB ID 3MXF) as starting model. The resulting model had an Rcryst/ Rfree of 22.1/ 
26.1%, and the electron density map showed a strong signal for a bound JD1 molecule. 
Phenix.elbow 43 was used to generate ligand restraints for JD1. Restraints for the ferrocene 
moiety were manually adjusted using the geometry of the ferrocene group present in PDB ID 
1A3L as a template. Likelihood-weighted 2mFo-DFcalc and mFo-DFCalc maps allowed 
unambiguous modelling of the thienotriazolodiazepine core of JD1, but the orientation and 
location of the ferrocene group remained ambiguous. 
A second dataset from the same crystal was collected on beamline I04 at the Diamond Light 
Source at a wavelength of 1.7384 Å, just below the Fe K-edge, with the aim of using the 
anomalous signal of Fe to locate the position of the iron atom of the ferrocene group. Model 
phases from initial refinement and the measured anomalous differences were used as input and 
the resulting anomalous difference Fourier map displayed two outstanding peaks with an r.m.s. 
density of 8.9 and 7.5, respectively, in the ambiguous region. The ferrocene moiety was modelled 
in two conformations with occupancies of 0.66 and 0.34, respectively. 
After several rounds of manual rebuilding in COOT44 and subsequent cycles of refinement with 
REFMAC5 40, Rcryst/ Rfree of 14.9% and 17.9%, respectively. The model and structure factors 
were deposited in the Protein Data Bank (PDB) under accession number 6SE4. 
Raw diffraction images of both datasets and ligand restraints for JD1 are available at the 
ZENODO data repository (10.5281/zenodo.3063129).  
 
Data collection and refinement statistics are summarized in Table S1. The model and structure 





A mixture of (+)-JQ-1 (200 mg, 0.438 mmol) and anhydrous DCM (50 mL) was cooled to 0 °C.  
To the mixture was added dropwise trifluoroacetic acid (20 mL) and the resulting mixture was 
warmed to ambient temperature and stirred for 16 h under an argon atmosphere. The reaction 
was concentrated under reduced pressure and to the residue was added a 1:1 mixture of 
DCM:Et2O. The solvent was removed under reduced pressure and the sequence repeated five 
times to give (+)-JQ-1-OH as a yellow solid of sufficient purity to be utilised in subsequent 




To (+)-JQ-1-OH (176 mg, 0.438 mmol) was added anhydrous THF (20 mL) and anhydrous DIPEA 
(153 µL, 0.876 mmol) under an argon atmosphere. To the resulting mixture was added HBTU 
(332 mg, 0.876 mmol) and aminoferrocene (176 mg, 0.876 mmol) and the mixture stirred at 
ambient temperature for 16 h. To the mixture was added DCM (50 mL) and a solution of 2M 
aqueous NaOH (25 mL). The biphasic mixture was separated and the resulting organic extract 
washed with a solution of 2M HCl (25 mL) followed by brine (25 mL), dried over anhydrous 
MgSO4, filtered, and concentrated under reduced pressure to give a brown solid (340 mg). The 
resulting residue was purified by automated flash column chromatography (EtOAc/MeOH, 100:0 
– 90:10, 45 g SiO2). The appropriate fractions were combined and concentrated under reduced 
pressure to give (+)-JD-1 as a dark yellow solid (205 mg, 80% over two steps). LCMS (UV, ESI) 
Rt = 21.07 min, [M+H]+ m/z  = 583.0, 100% purity. 1H NMR (600 MHz, d6 −DMSO): δ = 9.67 (1H, 
15 
 
s), 7.51-7.46 (4H, m), 4.63 (1H, m), 4.60-4.55 (2H, m), 4.11 (5H, s), 3.97-3.94 (2H, m), 3.36-3.31 
(2H, m), 2.61 (3H, s), 2.42 (3H, s), 1.64 (3H, s). 13C NMR (151 MHz, d6 −DMSO): δ = 168.1, 163.2, 
155.1, 149.8, 130.79, 130.2, 129.8, 129.6, 128.5, 95.4, 68.8, 63.8, 60.9, 60.4, 54.0, 14.1, 12.7, 
11.3. HRMS (ESI[M+H+]) m/z: Calcd for C29H26ClFeN5OS 583.0891; Found 583.0907. [α]D = + 




To (+)-JQ-1-OH (88 mg, 0.218 mmol) was added anhydrous THF (10 mL) and anhydrous DIPEA 
(79 µL, 0.436 mmol) under an argon atmosphere. To the resulting mixture was added HBTU (166 
mg, 0.436 mmol) and 4-(aminophenyl)ferrocene (121 mg, 0.436 mmol) and the mixture stirred at 
ambient temperature for 24 h. To the mixture was added EtOAc (25 mL) and water (25 mL) and 
the resulting biphasic mixture separated. The aqueous phase was extracted with EtOAc (2 x 25 
mL) and the combined organic extracts washed with brine (50 mL), dried over anhydrous MgSO4, 
filtered, and concentrated under reduced pressure to give a brown gum (600 mg). The resulting 
residue was purified by automated flash column chromatography (EtOAc/MeOH, 100:0 – 85:15, 
40 g SiO2). The appropriate fractions were combined and concentrated under reduced pressure 
to give (+)-JD-2 as a light brown solid (119 mg, 83%). LCMS (UV, ESI) Rt = 25.37 min, [M+H]+ 
m/z  = 659.0, 100% purity. 1H NMR (600 MHz, d6 −DMSO): δ = 10.31 (1H, s), 7.58 (2H, d, J = 8.4 
Hz), 7.50-7.46 (4H, m), 7.44 (2H, d, J = 8.3 Hz), 4.74-4.72 (2H, m), 4.62 (1H, t, J = 7.1 Hz), 4.32-
4.29 (2H, m), 4.01 (5H, s), 3.52 (2H, d, J = 7.1 Hz), 2.61 (3H, s), 2.42 (3H, s), 1.64 (3H, s). 13C 
NMR (151 MHz, d6 −DMSO): δ = 168.4, 163.2, 155.1, 149.9, 137.2, 136.7, 135.2, 133.6, 132.3, 
130.8, 130.1, 129.9, 129.6, 128.5, 126.1, 119.1, 84.9, 69.3, 68.6, 65.9, 53.8, 14.1, 12.7, 11.3. 
HRMS (ESI[+H]) m/z: Calcd for C35H30ClFeN5OS 659.1204; Found 659.1241. [α]D = -20.0 (t = 



















(-)-JD-1 was synthesised utilising the analogous protocol detailed above starting from (-)-JQ-1 
(20 mg, 0.044 mmol) to give (-)-JD-1 as a dark yellow solid (15 mg, 58% over two steps). 1H NMR 
and LCMS were in agreement with those reported above. Enantiomeric excess (ee) = 98.9% ee 
by chiral HPLC.   
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